Betta Pharma claims rights to Agenus' immunotherapies
Hangzhou's Betta Pharmaceuticals agreed to terms with Agenus, based in Lexington, Mass., to co-develop and commercialize two of its immunotherapies for the mainland China, Hong Kong, Macau, and Taiwan markets.
The Shenzhen-listed company will pay Agenus $35 million upfront and $100 million in potential milestones and royalties for cancer treatments balstilimab and zalifrelimab. In return, Betta gets the exclusive rights for the two immunotherapies either as monotherapies or combination therapies, excluding intravesical delivery.
Balstilimab is an anti-PD-1 therapy which is expected to be filed for U.S. approval this year as a monotherapy or paired with zalifrelimab, an anti-CLTA-4 drug, to treat refractory or metastatic cervical cancer. It was granted fast track designation by the FDA in April.
The Shenzhen-listed company will pay Agenus $35 million upfront and $100 million in potential milestones and royalties for cancer treatments balstilimab and zalifrelimab. In return, Betta gets the exclusive rights for the two immunotherapies either as monotherapies or combination therapies, excluding intravesical delivery.
Balstilimab is an anti-PD-1 therapy which is expected to be filed for U.S. approval this year as a monotherapy or paired with zalifrelimab, an anti-CLTA-4 drug, to treat refractory or metastatic cervical cancer. It was granted fast track designation by the FDA in April.
No hay comentarios:
Publicar un comentario